| pubmed-article:14518725 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0205466 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0005477 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0019189 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0035525 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C1446409 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:14518725 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:14518725 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:14518725 | pubmed:dateCreated | 2003-10-1 | lld:pubmed |
| pubmed-article:14518725 | pubmed:abstractText | Combination therapy of PEG-IFN alpha-2a o alpha-2b plus ribavirin represents a further improvement in treatment of chronic hepatitis HCV+ with a sustained virological response (SVR) either in monotherapy (25-39%) either in association with ribavirin (59-56%). SVR is highly predictable: 75% of all patients who achieve viral clearance at week 12 (EVR), if they had an adherence > 80% of planned therapy, they become sustained viral responders. In spite of virological response, 16-34% of patients on PEG-IFN monotherapy have high value of ALT, and this make them to reduce adherence. 62 patients whith chronic hepatitis HCV+ and no corrhosis, have been treated for 48 weeks with PEG-IFN and ribavirin to evaluate discrepancy incidence between virological (HCVRNA < 200UI) and biochemical (normal value of ALT) response of patients treated with PEG-IFN plus ribavirin and to verify the impact that stuch discrepancy can produce on SVR of treated patients. Our preliminary data confirm that PEG-IFN bring a superior virological response than biochemical one, either on naive patients either on experienced ones even with ribavirin in association. It will be useful to verify if this discepancy cause a superior SVR as already reported by several studies. Even the follow-up of our 5 discordant patients confirm this trend. | lld:pubmed |
| pubmed-article:14518725 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14518725 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14518725 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14518725 | pubmed:issn | 0393-974X | lld:pubmed |
| pubmed-article:14518725 | pubmed:author | pubmed-author:MazzottaFF | lld:pubmed |
| pubmed-article:14518725 | pubmed:author | pubmed-author:BlancP LPL | lld:pubmed |
| pubmed-article:14518725 | pubmed:author | pubmed-author:PierottiPP | lld:pubmed |
| pubmed-article:14518725 | pubmed:author | pubmed-author:BoxVV | lld:pubmed |
| pubmed-article:14518725 | pubmed:author | pubmed-author:MariniDD | lld:pubmed |
| pubmed-article:14518725 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14518725 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:14518725 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14518725 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14518725 | pubmed:pagination | 205-6 | lld:pubmed |
| pubmed-article:14518725 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:meshHeading | pubmed-meshheading:14518725... | lld:pubmed |
| pubmed-article:14518725 | pubmed:articleTitle | Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin. | lld:pubmed |
| pubmed-article:14518725 | pubmed:affiliation | Department of Infectious Diseases, S.M. Annunziata Hospital, ASL, Florence, Italy. | lld:pubmed |
| pubmed-article:14518725 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14518725 | pubmed:publicationType | Clinical Trial | lld:pubmed |
